Fuquan Jiang

Dr. Fuquan Jiang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in ACS Omega
Verified
Journal Article
Open access
LZLai Zhao
Lai Zhao
JHJiansong Han
Jiansong Han
FJFuquan Jiang
Fuquan Jiang
BLBo Li
Bo Li
SLShuang Lu
Shuang Lu
Jingjing LiJingjing Li
Jingjing Li
Nanodrugs have attracted increasing interest in drug delivery and disease treatment. However, the cumbersome preparation process and the poor biocompatibility of nanodrugs obstruct their clinical translation. In this study, we utilized a self-assembly strategy to develop a low-toxicity, long-lasting nanodrug for the effective treatment and real-time monitoring of bladder tumors. The accurate self-assembly of compatible raw materials allowed for an encapsulation rate of 43.7% for insoluble erdafitinib. Interestingly, robust therapeutic effects and reduced side effects could be realized simultaneously using this nanodrug, enabling broader scenarios for the clinical application of erdafitinib. Furthermore, the nanodrug exhibited a significantly prolonged in vivo half-life (14.4 h) and increased bioavailability (8.0 mu g/mL & BULL;h), which were 8.3 times and 5.0 times higher than those of its nonformulated counterpart. Also, it is worth mentioning that the introduction of a fluorescent protein module into the nanodrug brought up a novel possibility for real-time feedback on the therapeutic response. In conclusion, this research revealed a versatile technique for developing low-toxicity, long-acting, and multifunctional nanoformulations, paving the way for multidimensional therapy of malignant tumors.

7 November 2025 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
YWYalong Wu
Yalong Wu
JHJiansong Han
Jiansong Han
YLYang Li
Yang Li
FJFuquan Jiang
Fuquan Jiang
JHJiansong Han
Jiansong Han